NASDAQ · CRSP
CRISPR Therapeutics AG
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRSP: Nov 9, 2026
CRISPR Therapeutics AG Common Shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.06. The reported EPS for the same quarter last year was $-1.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.06 | $-0.61 | $-1.30 | 8 |
| Dec 2026 | $-1.21 | $-0.55 | $-1.87 | 7 |
| Mar 2027 | $-0.89 | $-0.37 | $-1.27 | 4 |
| Jun 2027 | $-0.86 | $-0.33 | $-1.19 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Zacks · The Motley Fool · RTTNews- BNK Invest · Oct 28, 11:01 AM EDTARK Innovation ETF Experiences Big OutflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ARK Innovation ETF (Symbol: ARKK) where we have detected an approximate $186.2 million dollar outflow — that's a 2.9% decrease week over week (from
- Zacks · Oct 27, 10:15 AM EDTVertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
- The Motley Fool · Oct 24, 6:20 PM EDTForget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreOne of CRISPR Therapeutics’ leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy.
- The Motley Fool · Oct 24, 3:29 PM EDTVertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.The biotech company has grown its annual revenue by more than 600% over the past decade.
- Zacks · Oct 23, 4:50 PM EDTCRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowIn the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
- Zacks · Oct 23, 8:00 AM EDTInvestors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to KnowRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
- Zacks · Oct 22, 5:00 PM EDTCRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should KnowCRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
- Zacks · Oct 21, 8:30 AM EDTBrokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a BetThe average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
- RTTNews · Oct 20, 1:56 AM EDTCRISPR Therapeutics Names A.J. Silver CFO As Raju Prasad Departs(RTTNews) – CRISPR Therapeutics Inc. (CRSP), a biopharmaceutical company, announced that Chief Financial Officer Raju Prasad, PhD, will step down to pursue other opportunities, and A.J. Silver, currently Senior Vice President of Finance, will succeed him as CFO effective immediat
- The Motley Fool · Oct 18, 5:33 PM EDTWhere Will CRISPR Therapeutics Stock Be in 2030?CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term.
- The Motley Fool · Oct 18, 7:10 AM EDTCathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRISPR Therapeutics' shares have declined more than 25% over the past year.
- Zacks · Oct 16, 4:50 PM EDTCRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to KnowCRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for CRISPR Therapeutics AG from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.